Zobrazeno 1 - 10
of 192
pro vyhledávání: '"Factor IX concentrate"'
Autor:
G. R. Cuadra, Rodriguez R, Martinez Mc, Rodriguez Gr, Marinsaldi A, María E. Bernardi, Hugo A. Guglielmone, Valdomero A
Publikováno v:
Annals of Hematology & Oncology. 8
The risk of thromboembolism with FIX replacement therapy remains a concern for hemophilic B patients. Previous studies from our laboratory demonstrated that the activated factor content of the FIX Plasma Derived (FIXpd) manufactured at UNC-Hemoderiva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5482e81d1a0a9080aee887d53250d2e9
https://doi.org/10.26420/annhematoloncol.2021.1343
https://doi.org/10.26420/annhematoloncol.2021.1343
Publikováno v:
Journal of pediatric hematology/oncology. 43(4)
A 16-year-old boy with severe hemophilia B and minimal bleeding manifestations in his early childhood presented with gastrointestinal bleeding at 11 years of age. Following administration of prothrombin complex concentrate, he developed peripheral ve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb2164d65262b550f6634ae171b9160d
https://pubmed.ncbi.nlm.nih.gov/32769563
https://pubmed.ncbi.nlm.nih.gov/32769563
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Value in health regional issues. 3
Objective: This study aimed to evaluate the cost-utility of the homebased care policy versus the no home-based care policy of factor VIII and factor IX concentrate in Thai patients with hemophilia A and B who had no inhibitor or less than 5 Bethesda
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eaeb9caa3e3f4e818319046cbdfbbce1
https://pubmed.ncbi.nlm.nih.gov/29702941
https://pubmed.ncbi.nlm.nih.gov/29702941
Autor:
Giancarlo Castaman, Giuseppe Tagariello, Marusia Valentina Uscatescu, Alessandra Borchiellini, Albert Farrugia, Massimo Morfini, Margit Serban, Cristina I. Truica, Elena Santagostino
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 25(6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1564bcc0502d0bf109c60bfba72aa538
https://pubmed.ncbi.nlm.nih.gov/31509326
https://pubmed.ncbi.nlm.nih.gov/31509326
Autor:
P. Laguna, Liana Gercheva, M. K. Woodward, José A. Aznar, A. Paez, K. Zavilska, A. Antonov, N. Cabrera, M. Matysiak, T. Lissitchkov
Publikováno v:
Haemophilia. 17:590-596
Effective treatment with factor IX (FIX) requires a thorough consideration of the properties of the concentrate to be used as replacement therapy, to date, the only available treatment for haemophilia B. The aim of the study was to determine the phar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::324dc6fc2247eea625f4e43f43316487
https://doi.org/10.1111/j.1365-2516.2010.02470.x
https://doi.org/10.1111/j.1365-2516.2010.02470.x
Publikováno v:
Haemophilia. 16:240-246
Summary. Factor IX Grifols® is a new high-purity plasma-derived FIX concentrate with two specific pathogen elimination steps. Until this study was performed, there were no detailed reports with an adequate number of patients on the clinical evaluati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7a4d84eab17266700e5e9da3520ffe70
https://doi.org/10.1111/j.1365-2516.2009.02090.x
https://doi.org/10.1111/j.1365-2516.2009.02090.x
Autor:
S. Cinotti, P. Rossi Ferrini, Massimo Morfini, Giovanni Longo, Andrea Messori, G. Giustarini, E. Filimberti
Publikováno v:
European Journal of Haematology. 39:426-433
We studied the pharmacokinetic data of 13 subjects with hemophilia B treated with a single-dose of a Factor IX concentrate (Bebulin TIM2, N = 9; Preconativ, N = 4). The decay curves of Factor IX were evaluated by model-independent methods and the fol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcb21d6a0e3cfbc10928449169ae3336
https://doi.org/10.1111/j.1600-0609.1987.tb01450.x
https://doi.org/10.1111/j.1600-0609.1987.tb01450.x
Autor:
Mandelli F, A Capitanio, P. M. Mannucci, Massimo Morfini, U. Baicchi, Ferrini Pl, F. Panicucci, Guglielmo Mariani, Petrucci F
Publikováno v:
Scandinavian Journal of Haematology. 16:41-47
Prophylaxis replacement therapy has been assessed for a period of 12 months in 10 patients with severe haemophilia B showing a high incidence of spontaneous bleeding episodes. Two different schedules of administration of a freeze-dried factor IX conc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08d37f5a0d782d7b43f558481c58982d
https://doi.org/10.1111/j.1600-0609.1976.tb01115.x
https://doi.org/10.1111/j.1600-0609.1976.tb01115.x
Publikováno v:
Scandinavian Journal of Haematology. 33:379-382
T cell subpopulations were determined in 88 Swedish patients with severe hemostatic disorders treated with domestic or imported American factor VIII or Swedish factor IX preparations at two centres, Karolinska hospital (KH) and Malmo hospital (MH). A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d20119d03bc12a41fe8cbe4e83c14033
https://doi.org/10.1111/j.1600-0609.1984.tb02590.x
https://doi.org/10.1111/j.1600-0609.1984.tb02590.x